Drug intelligence / Profile preview

NADvantage

Development stage: Unknown
Lead developer: Olympia Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

NADvantage is a topical compounded skincare formulation developed by Olympia Pharmaceuticals as part of their dermatology line. It contains 10% Nicotinamide Adenine Dinucleotide (NAD+), a coenzyme essential for cellular energy production and DNA repair. The product is designed to replenish declining NAD+ levels in skin cells, thereby supporting mitochondrial function and promoting collagen production. It is primarily indicated for cosmetic and dermatological use to address visible signs of skin aging, such as fine lines, wrinkles, and reduced elasticity, while also strengthening the skin barrier and protecting against environmental stressors.

Brand names: NADvantage
Other names: 10% Nicotinamide Adenine Dinucleotide creamNAD+ cream

Targets

NAD (Nicotinamide adenine dinucleotide)

Beyond the preview

Go deeper on NADvantage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADvantage.

Explore the full profile